Inhibitor Therapeutics, Inc. (INTI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Inhibitor Therapeutics, Inc. (INTI) trades at $0.08. Inhibitor Therapeutics, Inc. is a pharmaceutical development company focused on developing and commercializing therapeutics for cancer and non-cancerous proliferation disorders. Market cap: $13.81M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for INTI: INTI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates INTI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
INTI: 1/1 perspectives are bearish.
How is this calculated? →Inhibitor Therapeutics, Inc. (INTI) Healthcare & Pipeline Overview
Inhibitor Therapeutics, Inc., operating in the biotechnology sector, focuses on developing and commercializing therapeutics for cancer and non-cancerous proliferation disorders. Their primary focus is on SUBA-Itraconazole, an oral formulation of itraconazole, targeting prostate and lung cancer, with a completed Phase 2b study for basal cell carcinoma nevus syndrome.
What Is the Investment Thesis for INTI?
Inhibitor Therapeutics, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on SUBA-Itraconazole for prostate and lung cancer, along with positive Phase 2b data for basal cell carcinoma nevus syndrome, offers potential upside. However, the company's small market capitalization of $13.81M and negative P/E ratio of -4.43 indicate significant financial challenges. The company's success hinges on the successful completion of clinical trials and subsequent commercialization of SUBA-Itraconazole. Key value drivers include positive clinical trial results, strategic partnerships, and regulatory approvals. The negative beta of -0.36 suggests a potential lack of correlation with the broader market, which could offer diversification benefits. However, the OTC listing introduces liquidity and regulatory risks.
Based on FMP financials and quantitative analysis
INTI Key Highlights
- Market capitalization of $13.81M indicates a micro-cap company with potential for high growth but also significant risk.
- Negative P/E ratio of -4.43 reflects the company's current lack of profitability and reliance on future drug development success.
- Beta of -0.36 suggests a potential lack of correlation with the broader market, which could offer diversification benefits.
- Focus on SUBA-Itraconazole, an oral formulation of itraconazole, targeting prostate and lung cancer, offering a potentially novel treatment option.
- Positive Phase 2b study completed for SUBA-Itraconazole in the treatment of basal cell carcinoma nevus syndrome, demonstrating potential efficacy.
Who Are INTI's Competitors?
INTI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BETRF BetterLife Pharma Inc. | $0.13 | +3.37% | $21.84M | 45 |
| CUBT Curative Biotechnology, Inc. | $1.00 | +49.63% | $6.82M | 42 |
| DVHGF Devonian Health Group Inc. | $7.00 | +0.00% | $19.47M | 47 |
| LIANY LianBio | $0.16 | +39.04% | $17.45M | 51 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are INTI's Key Strengths?
- Proprietary SUBA-Itraconazole formulation.
- Positive Phase 2b clinical trial data for basal cell carcinoma nevus syndrome.
- Experienced management team.
- Focus on unmet medical needs in oncology.
What Are INTI's Weaknesses?
- Limited financial resources.
- Small market capitalization.
- Dependence on the success of SUBA-Itraconazole.
- OTC listing introduces liquidity and regulatory risks.
What Could Drive INTI Stock Higher?
- Announcement of results from ongoing clinical trials of SUBA-Itraconazole for prostate and lung cancer.
- Potential strategic partnerships for clinical development and commercialization.
- Regulatory submissions for SUBA-Itraconazole in various cancer indications.
- Continued development of novel drug delivery systems for itraconazole.
- Exploration of geographic expansion into international markets.
What Are the Key Risks for INTI?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals for SUBA-Itraconazole.
- Unfavorable clinical trial results.
- Competition from larger pharmaceutical companies.
- Limited financial resources.
- Dependence on the success of SUBA-Itraconazole.
What Are the Growth Opportunities for INTI?
- Expansion of SUBA-Itraconazole into additional cancer indications: Inhibitor Therapeutics can explore the potential of SUBA-Itraconazole in treating other types of cancer beyond prostate and lung cancer. The market for cancer therapeutics is projected to reach $200 billion by 2028, offering significant revenue potential. This expansion would require further clinical trials and regulatory approvals, potentially taking 3-5 years.
- Strategic partnerships for clinical development and commercialization: Collaborating with larger pharmaceutical companies can provide Inhibitor Therapeutics with access to funding, expertise, and infrastructure needed to advance SUBA-Itraconazole through clinical trials and commercialization. The timeline for securing such partnerships can vary, but typically takes 1-2 years. Successful partnerships can significantly accelerate the development and commercialization process.
- Out-licensing or sale of SUBA-Itraconazole: Inhibitor Therapeutics could out-license or sell the rights to SUBA-Itraconazole to a larger pharmaceutical company, generating upfront revenue and potential milestone payments. The market for licensing deals in the pharmaceutical industry is active, with deal values ranging from millions to billions of dollars. This strategy could provide a quicker return on investment compared to pursuing independent commercialization.
- Development of novel drug delivery systems for itraconazole: Exploring new drug delivery systems for itraconazole could improve its efficacy and reduce side effects, enhancing its market potential. The market for drug delivery technologies is growing, driven by the demand for more effective and patient-friendly drug formulations. This development could take 2-4 years and require significant research and development investment.
- Geographic expansion into international markets: Expanding into international markets, such as Europe and Asia, can significantly increase the potential market for SUBA-Itraconazole. The global market for cancer therapeutics is substantial, with significant growth opportunities in emerging markets. This expansion would require regulatory approvals in each target market, potentially taking 3-5 years.
What Opportunities Does INTI Have?
- Expansion of SUBA-Itraconazole into additional cancer indications.
- Strategic partnerships for clinical development and commercialization.
- Out-licensing or sale of SUBA-Itraconazole.
- Development of novel drug delivery systems for itraconazole.
What Threats Does INTI Face?
- Competition from larger pharmaceutical companies.
- Failure to obtain regulatory approvals.
- Unfavorable clinical trial results.
- Patent expiration.
What Are INTI's Competitive Advantages?
- Proprietary SUBA-Itraconazole formulation.
- Patent protection for its therapies.
- Positive Phase 2b clinical trial data for basal cell carcinoma nevus syndrome.
- Expertise in developing and commercializing cancer therapeutics.
What Does INTI Do?
Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Originally named HedgePath Pharmaceuticals, Inc., the company rebranded in August 2019 to Inhibitor Therapeutics, Inc. The company is dedicated to the development and commercialization of novel therapeutics aimed at treating patients suffering from various cancers and non-cancerous proliferation disorders. Their primary focus is on the development of therapies for prostate and lung cancer, utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole. The company has completed a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome, indicating potential efficacy in this area. Inhibitor Therapeutics operates within the biotechnology industry, concentrating on pharmaceutical development within the United States. The company's strategy revolves around identifying and developing targeted therapies that can address unmet medical needs in oncology and related fields. With a small team of 3 employees, Inhibitor Therapeutics is focused on advancing its pipeline and seeking strategic partnerships to support its clinical and commercialization efforts.
What Products and Services Does INTI Offer?
- Develops therapeutics for cancer and non-cancerous proliferation disorders.
- Focuses on therapies for prostate and lung cancer.
- Utilizes SUBA-Itraconazole, an oral formulation of itraconazole.
- Conducts clinical trials to evaluate the efficacy of its therapies.
- Seeks regulatory approvals for its therapies.
- Aims to commercialize its therapies in the United States.
How Does INTI Make Money?
- Develops and patents novel therapeutic compounds.
- Conducts preclinical and clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from the FDA.
- Commercializes approved therapies through partnerships or direct sales.
What Industry Does INTI Operate In?
Inhibitor Therapeutics, Inc. operates in the competitive biotechnology industry, characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The industry is driven by innovation and the development of novel therapies for unmet medical needs. The market for cancer therapeutics is substantial and growing, driven by an aging population and increasing cancer incidence rates. Competitors include companies developing similar therapies for prostate and lung cancer. Success in this industry requires strong scientific expertise, effective clinical trial execution, and strategic partnerships.
Who Are INTI's Key Customers?
- Patients with cancer and non-cancerous proliferation disorders.
- Healthcare providers who treat these patients.
- Pharmaceutical companies that may partner with or acquire Inhibitor Therapeutics.
Company Profile
Inhibitor Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Tampa, US. The company is led by CEO Francis E. O'Donnell Jr.. INTI has traded publicly since 2013.
F-Score 1/9Financial Health
Inhibitor Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Its free cash flow yield is -22.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.60 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -24.3%, the inverse of the P/E and a quick read on earnings relative to price.
INTI Valuation & Market Position
With a $13.81M market cap, Inhibitor Therapeutics, Inc. sits in the micro-cap segment of the market.
Net buyingInsider Activity
The most recent 10 insider filings for Inhibitor Therapeutics, Inc. break down as 0 sales and 10 purchases. On net that is roughly 500K shares acquired (about $0) — insiders putting money in tends to read as conviction.
INTI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying signals confidence in the company's future performance, suggesting a positive outlook.
- Community sentiment has shifted positively as recent developments in their drug pipeline have gained attention.
- Social media discussions highlight increasing optimism about their potential partnerships and collaborations.
- The market perceives strong growth potential due to the rising demand for innovative therapeutics in the industry.
Bear Case
- Concerns around the competitive landscape have emerged, with analysts noting several rivals advancing similar therapies.
- Recent community feedback has raised doubts about the speed of regulatory approvals for their key products.
- Negative sentiment has been fueled by delays in clinical trial results, leading to uncertainty among investors.
- Market perception is cautious, with some viewing the company's current valuation as inflated given the risks involved.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
INTI Latest News
No recent news available for INTI.
INTI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for INTI.
Price Targets
Wall Street price target analysis for INTI.
INTI MoonshotScore
What does this score mean?
The MoonshotScore rates INTI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Francis E. O'Donnell Jr.
CEO
Francis E. O'Donnell Jr. serves as the CEO of Inhibitor Therapeutics, Inc. His background includes extensive experience in the pharmaceutical and biotechnology industries. He has held various leadership positions in companies focused on drug development and commercialization. His expertise spans areas such as clinical trials, regulatory affairs, and business development. He is responsible for overseeing the strategic direction and operations of Inhibitor Therapeutics.
Track Record: Under Mr. O'Donnell's leadership, Inhibitor Therapeutics has focused on advancing the development of SUBA-Itraconazole for cancer treatment. A key milestone has been the completion of a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. He is managing a team of 3 employees.
INTI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Inhibitor Therapeutics, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited liquidity, price volatility, and information asymmetry.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity due to OTC listing.
- Potential for price manipulation.
- Lack of regulatory oversight.
- Information asymmetry.
- Higher risk of delisting.
- Verify the company's financial statements.
- Assess the company's management team and track record.
- Review the company's SEC filings (if any).
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal proceedings.
- Positive Phase 2b clinical trial data for SUBA-Itraconazole.
- Focus on developing therapies for unmet medical needs in oncology.
- Experienced management team.
- Patent protection for its therapies.
Common Questions About INTI (Healthcare)
What does Inhibitor Therapeutics, Inc. do?
Inhibitor Therapeutics, Inc. is a pharmaceutical development company focused on developing and commercializing therapeutics for patients with cancer and non-cancerous proliferation disorders. Their primary focus is on SUBA-Itraconazole, an oral formulation of itraconazole, which is being developed for the treatment of prostate and lung cancer. The company has completed a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome, demonstrating its potential in addressing unmet medical needs in oncology.
What do analysts say about INTI stock?
As of March 18, 2026, there is no available analyst coverage for Inhibitor Therapeutics, Inc. due to its small market capitalization and OTC listing. Key valuation metrics such as price targets and earnings estimates are not available. Investors should conduct their own independent research and consider the risks associated with investing in micro-cap stocks before making any investment decisions. The company's future growth prospects depend on the successful development and commercialization of SUBA-Itraconazole.
What are the main risks for INTI?
The main risks for Inhibitor Therapeutics, Inc. include the potential failure to obtain regulatory approvals for SUBA-Itraconazole, unfavorable clinical trial results, competition from larger pharmaceutical companies, limited financial resources, and dependence on the success of SUBA-Itraconazole. Additionally, the company's OTC listing introduces liquidity and regulatory risks. Investors should carefully consider these risks before investing in INTI.
What are the key factors to evaluate for INTI?
Evaluate INTI on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does INTI data refresh on this page?
INTI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven INTI's recent stock price performance?
Inhibitor Therapeutics, Inc. (INTI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary SUBA-Itraconazole formulation. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider INTI overvalued or undervalued right now?
Valuing Inhibitor Therapeutics, Inc. (INTI) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying INTI?
Before investing in Inhibitor Therapeutics, Inc. (INTI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than major exchange data.
- AI analysis pending for INTI.